Study Links Splicing Changes to Lung Cancer Immunotherapy

Researchers at The Jackson Laboratory identified cellular changes that correspond to how lung cancer patients respond to immunotherapy.

Updated on Nov. 2, 2026 in Cancer

Clear glass culture flasks of pale amber liquid on a steel laboratory bench, with a pipette resting across one flask, in soft daylight. — Researchers at The Jackson Laboratory identified splicing changes in lung cancer cells that correspond to how patients respond to immunotherapy. AI Illustration. Upload story photo >

Researchers at The Jackson Laboratory identified cellular alternative splicing changes associated with lung cancer patient response to immunotherapy. The findings were published in the journal Science.

Why it matters

An estimated 60% to 80% of lung cancer patients do not respond to certain types of immunotherapy, and lung cancer remains the leading cause of cancer-related deaths in the United States. Understanding the cellular patterns behind response could help clinicians better identify which patients are likely to benefit.

The study is a laboratory analysis of alternative splicing patterns, and the figures cited are the estimated 60% to 80% non-response rate to certain immunotherapies and lung cancer's rank as the second most common cancer in the United States. Further clinical trial testing is still needed to confirm how the identified cellular changes translate to patient outcomes.

The players

The Jackson Laboratory

The Jackson Laboratory is a Bar Harbor, Maine-based biomedical research institution and an NCI-designated cancer center known for genetic and cancer research.

Science

Science is a peer-reviewed scientific journal published by the American Association for the Advancement of Science that publishes influential research across disciplines.

The details

Rather than relying solely on standard DNA testing, researchers examined alternative splicing, the process by which cells interpret genetic instructions. They identified previously overlooked cellular changes that influence how lung cancer tumors interact with the immune system and correspond to differences in patient survival after immunotherapy.

The article reporting the findings was published on November 2, 2026.

Health Landscape

This work extends a shift in lung cancer research away from DNA-level biomarkers toward analyzing how cells process genetic instructions. It could inform efforts to personalize immunotherapy for a disease that remains the leading cause of cancer deaths in the United States.

For patients facing lung cancer, identifying which individuals are likely to respond to immunotherapy could influence whether this treatment is recommended, avoiding time and side effects from therapies that may not work. Clinical trial testing is expected to be needed before these patterns change everyday treatment decisions.

The takeaway

Lung cancer patients who do not respond to some immunotherapies may one day be identified earlier, as researchers work toward cellular markers that help doctors choose treatments. Patients should discuss treatment options and biomarker testing with their oncology team.